Who owns REGENERON PHARMACEUTICALS, INC.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of REGN from SEC Form 13F filings across 1,423 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 1,423 institutions disclosed 88.6M shares of REGENERON PHARMACEUTICALS, INC. worth $67.57B — about 87.1% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
1,423
13F holders
$67.57B
value, 2026 filers
87.1%
of shares outstanding (88.6M sh)
214
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of REGN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.8M | $6.71B | 0.1% | 8.7% | -2.9% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.5M | $4.95B | 0.1% | 6.4% | -1.6% |
| 3 | STATE STREET CORP | 4.9M | $3.70B | 0.1% | 4.8% | +1.0% |
| 4 | Dodge & Cox | 4.8M | $3.62B | 1.9% | 4.7% | -2.0% |
| 5 | Invesco Ltd. | 3.7M | $2.82B | 0.2% | 3.7% | -5.6% |
| 6 | JPMORGAN CHASE & CO | 3.3M | $2.48B | 0.1% | 3.3% | -12.4% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $2.36B | 0.1% | 3.1% | -2.0% |
| 8 | FRANKLIN TEMPLETON INC | 3.0M | $2.75B | 0.6% | 2.9% | +6.5% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $1.99B | 0.1% | 2.6% | +0.3% |
| 10 | Nuveen, LLC | 2.0M | $1.48B | 0.4% | 1.9% | -3.2% |
| 11 | LOOMIS SAYLES & CO L P | 1.7M | $1.30B | 1.7% | 1.7% | -7.7% |
| 12 | MORGAN STANLEY | 1.4M | $1.04B | 0.1% | 1.3% | -1.8% |
| 13 | AQR CAPITAL MANAGEMENT LLC | 1.3M | $978.9M | 0.3% | 1.3% | +16.5% |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 1.3M | $964.5M | 0.2% | 1.3% | +0.1% |
| 15 | BANK OF AMERICA CORP /DE/ | 1.2M | $884.4M | 0.1% | 1.1% | -9.7% |
| 16 | Amundi | 1.2M | $872.8M | 0.2% | 1.1% | +13.6% |
| 17 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.1M | $837.0M | 0.1% | 1.1% | -27.8% |
| 18 | FMR LLC | 1.0M | $785.0M | 0.0% | 1% | +24.4% |
| 19 | NORTHERN TRUST CORP | 997,639 | $756.5M | 0.1% | 1% | +8.9% |
| 20 | TWO SIGMA INVESTMENTS, LP | 869,505 | $659.3M | 0.5% | 0.9% | +32.5% |
| 21 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 854,258 | $647.8M | 0.1% | 0.8% | +19.2% |
| 22 | Capital World Investors | 832,633 | $631.4M | 0.1% | 0.8% | +2.2% |
| 23 | FIRST TRUST ADVISORS LP | 826,770 | $626.9M | 0.4% | 0.8% | +51.1% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 773,243 | $586.3M | 0.1% | 0.8% | -8.6% |
| 25 | Bank of New York Mellon Corp | 734,673 | $557.1M | 0.1% | 0.7% | -3.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.